妇科肿瘤HER2检测方法以及结果判读

参考文献：

[1] Shi H, Shao Y, Lu W, et al. An analysis of HER2 amplification in cervical adenocarcinoma: Correlation with clinical outcomes and the international endocervical adenocarcinoma criteria and classification[J]. Journal of Pathology: Clinical Research, 2021, 7(1): 86-95.

[2] Yan M, Schwaederle M, Arguello D, et al. HER2 expression status in diverse cancers: Review of results from 37,992 patients[J]. Cancer and Metastasis Reviews, 2015, 34(1): 157-164.

[3] Halle M K, Tangen I L, Berg H F, et al. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions[J]. British Journal of Cancer, 2018, 118(3): 378-387.

[4] Ross D S, Devereaux K A, Jin C, et al. Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas[J]. Modern Pathology, 2022, 35(7): 962-971.

[5] Buza N, English D P, Santin A D, et al. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice[J]. Modern Pathology, 2013, 26(12): 1605-1612.

[6] Ersoy E, Cao Q J, Otis C N. HER2 protein overexpression and gene amplification in tubo-ovarian high-grade serous carcinomas[J]. International Journal of Gynecological Pathology, 2022, 41(4): 313-319.

[7] Tuefferd M, Combe M. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients[J].

[8] 全慧霞, 林仲秋. 妇科肿瘤人表皮生长因子受体2相关研究进展及检测方法[J]. 中国实用妇科与产科杂志, 2024, 40(1): 74-84.

[9] Meric-Bernstam F, Makker V, Oaknin A, et al. Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study[J]. Annals of Oncology, 2023, 34: S1273-S1274.

[10] Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial[J]. Journal of Clinical Oncology, 2024, 42(1): 47-58.

[11] Xu M, Chen R, Xing P, et al. A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors[J]. Journal of Clinical Oncology, 2023, 41(16_suppl): e14614-e14614.

[12] 胃癌诊疗指南（2023）CSCO.